依普利酮不同版本一盒的最新价格公布

Introduction: Eplerenone is an important drug for the treatment of heart failure and hypertension. It is available in multiple versions around the world, with different prices and availability. This article compiles the latest price information of different versions of eplerenone in 2025, and introduces its domestic launch status and medical insurance reimbursement policy to help patients better understand medication choices.

The latest prices for a box of different versions of eplerenone

The prices in the international market in 2025 will vary depending on the manufacturer and specifications. The following prices are for reference only.

American Huizhi version

The specification of the original drug produced by American Huizhi is 50mg*100 tablets/box, and the latest price in 2025 is about US$85. This version has stable quality and accurate efficacy, and is the preferred treatment drug in many countries.

Indian Lupine version

The generic drug specifications produced by India Lupine are 50mg*150 tablets/box, and the latest price in 2025 is about US$88. Compared with the original drug, the Indian version has a lower unit price per tablet and is more cost-effective.

After understanding the international market price, let’s take a look at the domestic supply of eplerenone.

The domestic market status of eplerenone

Eplerenone has been officially launched in China, providing new treatment options for relevant patients.

Time on the market

Eplerenone was approved for marketing by the China National Medical Products Administration in 2020, with the trade name "Eplerenone". It is currently sold in major hospitals and regular pharmacies.

Domestic specifications

The domestically marketed eplerenone mainly comes in two specifications: 25mg and 50mg, and the common packaging is 28 tablets/box. In terms of price, the 50mg specification is approximately RMB 480-550 per box.

In addition to understanding drug supply, patients should also pay attention to medical insurance reimbursement policies.

Reimbursement status of eplerenone by medical insurance

Eplerenone has been included in some medical insurance catalogs, but reimbursement policies vary by region.

National Medical Insurance Catalog

Eplerenone is currently included in the National Medical Insurance Drug Catalog, with a reimbursement ratio of approximately 50%-70%. The specific reimbursement amount must refer to local medical insurance policies.

Differences in local medical insurance

There are differences in the reimbursement policies for eplerenone in different provinces. For example, first-tier cities have a higher reimbursement ratio, and some economically underdeveloped areas may not be included in local medical insurance.

Patients can consult the local medical insurance department or hospital pharmacy to learn about the specific reimbursement policies and conditions of use before purchasing medicines.